Trial Profile

Randomized Phase II Study of BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 Jan 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dactolisib (Primary) ; Everolimus
Indications Neuroendocrine tumours; Pancreatic cancer
Focus Therapeutic Use
Acronyms MACS1938
Sponsors Novartis

Most Recent Events

25 Jan 2019 This trial has been completed in UK - MHRA, according to European Clinical Trials Database.
09 Mar 2016 Status changed from completed to discontinued based on an interim analysis as BEZ235 did not demonstrate a progression free survival advantage to everolimus treatment, according to ClinicalTrials.gov record.
02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com